Day One

• Unveiling the process and strategy in obtaining first domestic CAR-T therapy in Korea
• Sharing the commercialization and expansion plan for approved CAR-T therapy
• Outlining future development plans

• Exploring multi-edit allogeneic CAR-T engineering strategies, including checkpoint disruption and immune cloaking, designed to enhance persistence and antitumor activity
• Reviewing clinical data supporting durable efficacy, rapid treatment access, and scalable manufacturing across lymphoma and multiple myeloma programs
• Sharing the role of precision genome editing in enabling next-generation off-the-shelf cell therapies with the potential to broaden global patient access

• Designing multi-armored T cell therapies to overcome tumor resistance mechanisms
• Engineering armored CAR and TCR constructs specifically optimized for in vivo cell therapies
• Advancing first- and best-in-class multi-armored in vivo cell therapies for solid tumors

Get face-to-face with many of the brightest minds working in the cell and gene therapy field and establish meaningful business relationships to pursue for the rest of the conference. As part of the World Advanced Therapeutics Summit South Korea, attendees will also be able to networking with experts working on the RNA field.

Hear from executive leaders who will discuss their ambitions, strategies and challenges for the future cell and gene therapies, the hottest indications of unmet need and progress towards the next commercial approval, which include:

• What are the future opportunities, promising targets and applications on the horizon for cell and gene therapies to achieve clinical success?
• What are the current industry’s top priorities and upcoming hurdles to development, such as investment, manufacturing, pricing and reimbursement and commercialization to better prepare and strategize to navigate the evolving landscape
• How to structure successful biotech–pharma–academia collaborations in South Korea to balance expectations and maximize the translational speed of your CAR-T, gene editing and therapeutic programs

• Sharing how NK cell therapy combined with HAIC for advanced HCC Phase 2a results showing 68.75% ORR and 100% Disease Control Rate
• Showcasing how to best expand NK cell therapy to additional solid tumors, including small cell lung cancer (SCLC) and pancreatic ductal adenocarcinoma (PDAC), alongside emergency trial cases
• Unveiling next-generation CAR platforms, CAR-MILs for multiple myeloma and dual PD-L1/EphA2 CAR-T for solid tumors, designed to overcome antigen escape and immunosuppression

Network with fellow attendees to share scientific insights on cell and gene therapy development, as well as with global service providers and those working in the RNA field.

• Exploring strategies for engineering next-generation CAR-T therapies for solid tumors
• Outlining process optimization approaches to shorten CAR-T manufacturing timelines while maintaining product quality and functionality
• Developing scalable and cost-effective CAR-T production workflows

• Introducing BNX-IFS™, a functional immune interaction profiling platform beyond conventional phenotyping
• Presenting translational and clinical data on dynamic neutrophil–T cell interaction states during immunotherapy and virotherapy
• Discussing real-time immune monitoring for biomarker discovery and next-generation cell and gene therapy development

As the landscape of innovation is enabling scalable and cost-effective cell and gene therapies, it is more important than ever to collaborate and learn for the growth of this field. Join our dedicated poster session to share your latest data and have a first look into what your peers are working on.

• Exploring how to leverage innate‑like recognition of stress‑induced antigens to defining indications where gamma delta T cells offer superior tumor surveillance compared with NK and T cells, particularly in heterogeneous or immune‑evasive tumors
• Identifying disease settings in which NK cells provide enhanced therapeutic benefit, including solid and liquid tumors through natural cytotoxicity and off‑the‑shelf compatibility
• Exploring combinatorial and multimodal strategies incorporating monoclonal antibodies, checkpoint inhibitors, cytokines, or other immunomodulators to amplify cellular immune responses, overcome tumor‑mediated immunosuppression, and achieve more durable tumor eradication

• Overview of iPS Bio’s translational strategy for Huntington’s disease, integrating disease-modifying small-molecule approaches with allogeneic iPSCderived neural precursor cell therapy
• Exploring the preclinical development of iPS Bio’s therapeutic programs, including patient-derived iPSC disease models, in vivo efficacy studies, mechanism-of-action considerations, and translational biomarkers
• Revealing key challenges and opportunities in advancing Huntington’s disease therapeutics toward clinical translation, including CMC, safety, regulatory strategy, patient selection, and global collaboration

• Discussing the advantages of macrophages as an alternative cell therapy modality
• Highlighting the therapeutic landscapes of macrophage-based cell therapies